HER2阳性、三阴性和局限性乳腺癌.pdf

1、Saturday,March 1,2025ModeratorNeil Love,MDRahul Aggarwal,MDAditya Bardia,MD,MPHMitesh J Borad,MDVirginia F Borges,MD,MMScHarold J Burstein,MD,PhDRashmi Chugh,MDChristopher Flowers,MD,MSFacultyJonathan Goldman,MDNicole Lamanna,MDNatasha B Leighl,MD,MMSc Amit Mahipal,MD,MPH William K Oh,MD David M OMa

2、lley,MD Joyce OShaughnessy,MD Krish Patel,MDRichard F Riedel,MD Kerry A Rogers,MD Simron Singh,MD,MPHBrian M Slomovitz,MD Jonathan Strosberg,MD Saturday,March 1,2025Sunil Gandhi,MDMaen Hussein,MDMary Li,MD,PhD Vikas Malhotra,MDBradley J Monk,MDFrank Rodriguez,MDSavan Shah,MDFaye Yin,MDCo-ModeratorsD

3、isclosures for Moderator Neil Love,MDDr Love is president and CEO of Research To Practice.Research To Practice receives funds in the form of educational grants to develop CME/NCPD/ACPE activities from the following companies:AbbVie Inc,ADC Therapeutics,Alexion Pharmaceuticals,Amgen Inc,Array BioPhar

4、ma Inc,a subsidiary of Pfizer Inc,Arvinas,Astellas,AstraZeneca Pharmaceuticals LP,Aveo Pharmaceuticals,Bayer HealthCare Pharmaceuticals,BeiGene Ltd,Black Diamond Therapeutics Inc,Blueprint Medicines,Boehringer Ingelheim Pharmaceuticals Inc,Bristol Myers Squibb,Clovis Oncology,Coherus BioSciences,CTI

5、 BioPharma,a Sobi Company,Daiichi Sankyo Inc,Eisai Inc,Elevation Oncology Inc,Exact Sciences Corporation,Exelixis Inc,Genentech,a member of the Roche Group,Genmab US Inc,Geron Corporation,Gilead Sciences Inc,GSK,Hologic Inc,ImmunoGen Inc,Incyte Corporation,Ipsen Biopharmaceuticals Inc,Janssen Biotec

6、h Inc,administered by Janssen Scientific Affairs LLC,Jazz Pharmaceuticals Inc,Karyopharm Therapeutics,Kite,A Gilead Company,Legend Biotech,Lilly,MEI Pharma Inc,Merck,Mersana Therapeutics Inc,Mirati Therapeutics Inc,Mural Oncology Inc,Natera Inc,Novartis,Novartis Pharmaceuticals Corporation on behalf